Live Breaking News & Updates on N Combination With Select Toxsyn Linker Payloads Peter Van De Sande

Synaffix to provide Hummingbird Bioscience access to proprietary ADC technologies Synaffix to receive up to $150m in upfront and milestone payments plus royalties SAN FRANCISCO, HOUSTON and SINGAPORE, Jan. 4, 2023 /PRNewswire/ Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, and Hummingbird Bioscience (Hummingbird Bio), a data-driven precision biotherapeutics company using its Rational Antibody Discovery (RAD) platform to discover and engineer antibodies against optimal yet elusive epitopes, thereby unlocking novel mechanisms of action, today announced that they entered into a licensing agreement that will enable Hummingbird Bio to develop a next generation ADC program using Synaffix technology. Under the terms of the agreement, Synaffix will be eligible to receive up to $150 million, including upfront and milestone payments, ....

United States , Innovent Biologics , Platform Technology , Hummingbird Bioscience , Hummingbird Bio , Rational Antibody Discovery , Chief Executive Officer , Piers Ingram , Mersana Therapeutics , Shanghai Miracogen , Kyowa Kirin , Biogeneration Ventures , Synaffix To Provide Hummingbird Bioscience Access Proprietary Adc Technologies Receive Up 150m In Upfront And Milestone Payments Plus Royalties San Francisco , Ouston And Singapore , Jan 4 , 023 Prnewswire Synaffixbv Synaffix , A Biotechnology Company Focused On Commercializing Its Clinical Stage Platform Technology For The Development Of Antibody Drug Conjugates Adcs With Best In Class Therapeutic Index , Nd Hummingbird Bioscience Bio , A Data Driven Precision Biotherapeutics Company Using Its Rational Antibody Discovery Rad Platform To Discover And Engineer Antibodies Against Optimal Yet Elusive Epitopes , Hereby Unlocking Novel Mechanisms Of Action , Oday Announced That They Entered Intoa Licensing Agreement Will Enable Hummingbird Bio To Developa Next Generation Adc Program Using Synaffix Technology Under The Terms Of , Ynaffix Will Be Eligible To Receive Up 150 Million , Ncluding Upfront And Milestone Payments , Lus Royalties On Net Sales For The Target Licensed , Ummingbird Bio Is Granted Rights To Utilize Synaffix Proprietary Adc Technologies Glycoconnect And Hydraspace , N Combination With Select Toxsyn Linker Payloads Peter Van De Sande ,